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Ten years after the first inspection of a candidate European centre,
an EBMT registry analysis suggests that clinical outcome is improved
when hematopoietic SCT is performed in a JACIE accredited program
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In 2010, JACIE, the Joint Accreditation Committee of
ISCT (International Society for Cell Therapy) Europe and
EBMT (European group for Blood and Marrow Trans-
plantation) celebrated the tenth anniversary of the first
inspection of a European hematopoietic SCT program.
JACIE standards establish the criteria for a comprehensive
quality management program that covers all three major
domains of activity that are necessary for the delivery of
HSCT: clinical, collection and processing, as well as their
interactions with ancillary and supportive activities.
Although more than 200 European programs have applied
for JACIE accreditation, and more than 100 have been
granted accreditation, a recent retrospective analysis of the
large-size EBMT registry of autologous and allogenic
hematopoietic HSCT demonstrates that one of the factors
affecting the overall survival of recipients of allogenic
transplantation is the status of the transplant program
regarding JACIE accreditation. This provides one of the
first demonstrations that introduction of a quality manage-
ment system contributes to the overall survival of patients
treated with a highly specific medical procedure, and
represents a milestone in the implementation of JACIE.
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JACIE (Joint Accreditation Committee of ISCT Europe
and EBMT) was started in Europe at the end of the 1990’s,
with the support of the European group for Blood and
Marrow Transplantation (EBMT), and the European
branch of the International Society for Cell Therapy
(ISCT). JACIE pursues the same objectives as FACT
(Foundation for the Accreditation of Cell Therapy), the
accreditation program for hematopoietic SCT (HSCT)
activities in North America; both aim at promoting
excellence,1 harmonization and improving results of HSCT.
FACT-JACIE standards establish criteria for a compre-
hensive quality management program that covers all three
major domains of activity in HSCT—clinical, collection
and processing, as well as their interactions with ancillary
and support activities. The fourth version of the FACT-
JACIE standards was released in 2008. The fifth version is
currently being prepared for release in early 2012.
Reasons for implementing FACT-JACIE standards
include the complexity and diversity of the therapeutic
procedure, the production of cell-based medicinal products
by academic facilities rather than by pharmaceutical
companies, the necessary collaboration between various
hospital-based infrastructures and healthcare professionals,
the non-conventional use of cytotoxic and immune-
suppressive drugs,2 and the increasing use of unrelated
donors with international exchanges.3–7 Recognizing the
complex nature and multi-disciplinary approach necessary
for HSCT led JACIE to accredit ‘programs’ rather than
infrastructures, a significant difference to authorizations
issued by competent authorities to ‘facilities’.
The first inspection of a candidate program, that was
later granted accreditation, took place in 2000. Since then,
218 European professionals have been trained as inspec-
tors, of whom 150 have participated in at least one
inspection. A total of 216 HSCT programs have applied
from 17 European countries (See Figure 1). In all, 191
programs have been inspected, including 157 first inspec-
tions and 34 second inspections for re-accreditation; 133
programs have been accredited at least once, of which 102
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are currently accredited. This is a remarkable achievement
in the context of the linguistically, culturally and regulatory
diverse environment of Europe.
However, the question remains whether JACIE improves
patient outcome. The literature contains little evidence to
justify costs associated with quality management: human
resources, documents, communication1,8y . A retrospec-
tive analysis of the EBMT registry was recently conducted
on more than 100 000 HSCT performed between 1999 and
2007 at 421 different HSCT programs. The hypothesis was
that introduction of JACIE should lead to a stepwise
improvement in outcome, from baseline (43 years before
application or no application), to preparation
(3 years before application), to application (time from
application to accreditation), to after JACIE accreditation,
with a greater magnitude than expected by time alone.9
Confounding factors: EBMT risk factor for individual
patients, centre size, per-capita income in different coun-
tries,10,11 were included in the analysis, to eliminate
potential biases. Results provided support for the hypoth-
esis: a significant 14% increase in overall survival was
observed for patients with chronic leukemias who received
an allogenic HSCT in a JACIE-accredited program, as
compared with those treated in a non-accredited program.
Although mainly applicable to recipients of allogeneic
transplantation, improvement in overall and disease-free
survival was also apparent for recipients of high-dose
chemotherapy supported with autologous HSCT. The
major caveat associated with this study is the small number
of HSCT procedures performed in JACIE accredited
centres, which reflects both the relatively recent establish-
ment of the accreditation process, and the small proportion
of accredited programs among centres that report their
activity to EBMT. Nevertheless, this study provides one of
the first demonstrations that introduction of a quality
management system may be a factor in improving patient’s
overall survival, and so represents a milestone in the
implementation of JACIE.
A 14% improvement in survival is of the same order of
magnitude as that associated with major innovations in the
field: the design of new immunosuppressive regimens for
GVHD prophylaxis,12 substitution of aphereses for BM as
a source of transplantable cells,13 introduction of cord
blood units as an alternative source of hematopoietic stem
cells,14 or the design of non-myelo-ablative conditioning
regimes that favor the use of immunosuppressive rather
than cytotoxic agents.15
JACIE does not substitute for legal requirements: on the
contrary, a key criterion in FACT-JACIE standards is that
all active facilities comply with national, European and
international regulations. However, JACIE is unique in its
coverage of clinical and technical/biological activities: the
EBMT registry analysis supports the postulate that this
approach is clinically relevant and useful. It thus provides a
rationale for hospitals to invest resources in voluntary
accreditation, in addition to resources that they devote to
maintain mandatory authorizations for their activities. For
the JACIE board and executive committee, the clinical
benefit associated with accreditation is a strong incentive to
increase the proportion of European accredited programs.
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Figure 1 Proportion of initial JACIE applications for accreditation in
European countries.
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